Blood eosinophils in COPD: are biologics for everyone?

Ther Adv Respir Dis. 2026 Jan-Dec;20:17534666261471839. doi: 10.1177/17534666261471839. Epub 2026 Sep 19.ABSTRACTBACKGROUND: Type 2 (T2) biologics represent a promising treatment option for chronic obstructive pulmonary disease (COPD) patients with eosinophilic inflammation.OBJECTIVES: To evaluate t

M Marco Vanetti

Therapeutic Strategies for Takotsubo Syndrome: A Comprehensive Clinical Review

J Am Heart Assoc. 2026 Sep 18:e050906. doi: 10.1161/JAHA.126.050906. Online ahead of print.ABSTRACTTakotsubo syndrome (TTS), also known as stress-induced cardiomyopathy, is an acute reversible form of left ventricular systolic dysfunction that mimics acute coronary syndrome in presentation. Once reg

M Marco Giuseppe Del Buono

Clinical utility and tolerability of ketamine as adjunctive rescue therapy for refractory neonatal status epilepticus: a case report of a late preterm infant with multifocal hemorrhagic brain injury

Front Pediatr. 2026 Sep 3;14:1949800. doi: 10.3389/fped.2026.1949800. eCollection 2026.ABSTRACTBACKGROUND: Neonatal status epilepticus (NSE) is a life-threatening neurological emergency associated with high mortality and long-term neurodevelopmental morbidity. Although phenobarbital remains the reco

C Chiara Gulisano

Exercise-based cardiac rehabilitation for coronary heart disease

Cochrane Database Syst Rev. 2026 Sep 18;9(9):CD001800. doi: 10.1002/14651858.CD001800.pub5.ABSTRACTRATIONALE: Coronary heart disease (CHD) is the leading cause of death globally. CHD mortality rates remain steady in low- and middle-income countries but are declining in high-income countries, meaning

G Grace Dibben